Insilico Medicine Partners with Bora to Accelerate AI-Powered Drug Development

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd, a global leader in pharmaceutical manufacturing.

The proposed alliance will be governed by definitive agreements to be discussed and executed by Insilico and Bora and is designed to combine Insilico's proprietary Pharma.AI platform, spanning target discovery, generative chemistry, and molecule optimization, with Bora's global development, manufacturing, quality, and commercialization capabilities.  By linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution, Insilico and Bora aim to pioneer a next-generation drug innovation model that connects novel molecule design with the capabilities required to develop, manufacture, and deliver medicines to patients with unmet medical needs.

As part of the alliance, Insilico aims to accelerate Bora's transition toward more AI-driven and automation-driven drug discovery and development capabilities by providing comprehensive research and development strategies and end-to-end AI solutions across global discovery and development workflows. Over time, the alliance will further explore opportunities to apply AI and automation-driven approaches across development planning, process optimization, pharmaceutical development, manufacturing readiness, and quality systems.

"Insilico Medicine has established itself as one of the world's leading AI drug discovery companies by demonstrating that generative AI can identify novel targets, design novel molecules, and advance drug candidates into clinical development," said Bobby Sheng, founder, Chairman of Bora Group and CEO of Bora Pharmaceuticals. "This strategic alliance marks an important step in Bora's evolution from a leading pharmaceutical development and manufacturing partner into a broader drug innovation ecosystem. By combining Insilico's AI-native capabilities with Bora's global expertise in formulation, CMC, regulatory development, scale-up, quality, commercial manufacturing, supply chain, and commercialization, we have an opportunity to create a truly integrated pathway from discovery to commercialization.

"We are thrilled to partner with Bora, a visionary leader with world-class development and manufacturing capabilities and a strong commitment to AI-driven innovation," said Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of Insilico Medicine. "Building on our collaborations with Takeda and SK Biopharmaceuticals in Asia-Pacific, this alliance with Bora further demonstrates Insilico's commitment to partnering with leading biopharmaceutical innovators across the region. Insilico has built a powerful AI-native engine for target discovery, generative chemistry, and molecule optimization. Together with Bora, we aim to connect that discovery engine with the capabilities required to advance high-quality drug candidates through development, manufacturing, and potential commercialization, while also supporting Bora's broader AI transformation. This alliance represents an important step toward demonstrating how AI-discovered medicines can be developed faster, more efficiently, and with greater scalability."